Back

BMF Capital sees 74% downside for SELLAS ahead of Phase 3 readout

Verifying
  • BMF Capital disclosed a short position in SELLAS Life Sciences Group ahead of REGAL results.
  • BMF estimates SELLAS could fall roughly 74% to $3.50 per share if REGAL fails.
  • SELLAS said final analysis follows the trial's prespecified 80th death event.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.